Silverback Therapeutics Extends Series A to $47.5 Million to Advance Pipeline of First-in-Class Systemically Delivered, Locally Active Therapies

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/2QKOzMo
via IFTTT